Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of LP-184 in Patients with Advanced Solid Tumors
NCT05933265
Recruiting
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patie... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: John Hopkins - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
Register for Updates
Pragmatic Trial of Psilocybin Therapy in Palliative Care
NCT05403086
Recruiting
This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Sunstone Therapies, Rockville, Maryland
Conditions: Demoralization
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Maryland, Baltimore /ID# 243679, Baltimore, Maryland
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
NCT05120284
Recruiting
Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with recurrent GBM who have clinically indicated debulking surgery planned. No patients will be recruited at UF. Patients will be genotyped to establish safe dosing regimens and will be randomized to receive DCA (N=20) or no DCA (N=20) for one week prior to surgery. Deidentified blood and tumor tissue obtained at surgery will be assessed at UF for biochemical markers of DCA dynamics.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/03/2025
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Glioblastoma Multiforme
Register for Updates
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures
NCT04903314
Recruiting
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/03/2025
Locations: Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland
Conditions: Partial Epilepsy
Register for Updates
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618
Recruiting
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
03/01/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: C3G
Register for Updates
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527
Recruiting
The study design is a prospective, multi-center, single-arm, non-randomized post market clinical follow-up study to confirm the performance, safety and clinical benefit of the Integrity Implant System when used for rotator cuff tear augmentation (with or without repair).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Towson Orthopaedic Associates/University of Maryland St. Joseph's Medical Center, Towson, Maryland
Conditions: Rotator Cuff Tears of the Shoulder
Register for Updates
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
NCT06616597
Recruiting
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Register for Updates
Providing Evidence-Based Approaches for Caregiver Stress Study
NCT06451250
Recruiting
The purpose of this preliminary study is to examine the effects of adult day service use on subjective and physiological measures of stress in 50 Black informal caregivers for individuals with dementia (IWD). The PI of the proposed study has substantial training in primary data collection and complex-survey secondary data analysis, she also has the fundamental knowledge to investigate how sociocultural and behavioral factors can influence psychosocial stress. The proposed study will enroll parti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Caregiving Stress, Dementia
Register for Updates
Resilient, Engaged, and Connected Study
NCT06197997
Recruiting
Purpose of this study is to test the effectiveness and implementation of an evidence-based parenting intervention for improving parenting and school outcomes in a sample of 4-year-old children enrolled in public prekindergarten (PreK) programs in Maryland.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Johns Hopkins School of Nursing, Baltimore, Maryland
Conditions: Parenting, Parenting Intervention
Register for Updates
Asymptomatic Carotid Stenosis and Mobility Function With Exercise Intervention
NCT05436600
Recruiting
Moderate (50-69%) asymptomatic carotid artery stenosis (ACAS) is an important and under-appreciated contributor to balance and mobility dysfunction. This is significant because declines in balance and mobility are a significant predictor of falls, disability, loss of independence, and death in older adults. Further, falls and fall-related injuries in older adults cost approximately 50 billion dollars annually in the United States, and are the leading cause of adverse events reported by the Veter... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
02/28/2025
Locations: Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland
Conditions: Asymptomatic Carotid Stenosis (50-69%), Mobility Impairment
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Baltimore, Maryland
Conditions: Neoplasms
Register for Updates